GAROFALO HEALTH CARE GAROFALO HEALTH CARE S.P.A.: IL CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 31 MARZO 2026 / BOARD OF DIRECTORS APPROVES INTERIM FINANCIAL REPORT AT MARCH 31, 2026: management transactions · Italy · Consob

About GAROFALO HEALTH CARE GAROFALO HEALTH CARE S.P.A.: IL CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 31 MARZO 2026 / BOARD OF DIRECTORS APPROVES INTERIM FINANCIAL REPORT AT MARCH 31, 2026

Garofalo Health Care S.p.A. is a leading private accredited healthcare group in Italy, listed on Borsa Italiana (FTSE MIB) and headquartered in Rome. The company is positioned as an integrated private healthcare operator with a broad care offering spanning the full patient journey: high-, medium- and low-complexity surgery, medicine, clinical and interventional cardiology, motor/neurological/cardiac/nutritional rehabilitation, long-term and intensive care units, psychiatric facilities, and diagnostic centers. In its latest reporting, the group stated it operated through 38 healthcare clinics as of March 31, 2026, plus additional minority-associated facilities through Fi.d.es Medica. ([garofalohealthcare.com](https://www.garofalohealthcare.com/ghc/gruppo/chi-siamo)) The group’s origins date back to the 1950s, when Dr. Raffaele Garofalo, a surgeon and entrepreneur, helped build the first private healthcare group in the Lazio region together with his brothers Antonio and Mario. That family-rooted heritage remains part of the company’s identity, even as GHC has evolved into a diversified multi-site healthcare platform with a broader regional footprint. The parent company, Garofalo Health Care S.p.A., is based at Piazzale Belle Arti, 6 in Rome. ([garofalohealthcare.com](https://www.garofalohealthcare.com/index.php/en/garofalohealthcare/about-us?utm_source=openai)) From a competitive standpoint, GHC highlights a distinctive market position: it is the first and only Italian private accredited healthcare company listed on the Euronext STAR segment of Borsa Italiana. That listing status gives the company additional visibility among investors seeking defensive exposure, recurring demand, and disciplined M&A-led growth. The group also emphasizes cutting-edge medical technologies, including robotic-assisted surgery, and active research collaborations with Italian and international universities and institutions. ([garofalohealthcare.com](https://www.garofalohealthcare.com/ghc/gruppo/chi-siamo)) Geographically, GHC is concentrated in some of Italy’s strongest regions, including Lazio, Lombardy, Veneto, Emilia-Romagna, Liguria, Piedmont, Tuscany, and Friuli Venezia Giulia. Its asset base includes hospitals, clinics, outpatient centers, rehabilitation facilities, and specialized care structures. A major recent strategic move was the completion of the acquisition of Casa di Cura Città di Roma on January 19, 2026, a transaction that reinforces the group’s Rome cluster and its synergies with Aurelia Hospital and European Hospital. ([garofalohealthcare.com](https://www.garofalohealthcare.com/index.php/en/garofalohealthcare/about-us?utm_source=openai)) Recent events are important for investors. On May 14, 2026, the Board of Directors approved the interim financial report at March 31, 2026. First-quarter 2026 consolidated revenue reached €132.7 million, up 3.2% year on year, with the newly acquired entity already contributing to the numbers. The group also received a reaffirmation of its ESG rating by Standard Ethics in December 2025, and shareholders approved a €0.093 per-share dividend in April 2026. Overall, GHC remains a quality Italian healthcare name with structural support from the sector, though the equity story is influenced by acquisition integration, regional reimbursement dynamics, and execution on margin expansion. ([garofalohealthcare.com](https://www.garofalohealthcare.com/ghc/investor-relations/comunicati-finanziari))